Many people in India are now investing in IPOs. One of the new IPOs coming in October 2025 is from Rubicon Research Limited. This company works in the pharmaceutical field and is ready to sell its shares to the public for the first time. If you are planning to invest, it is important to understand what the company does, how much the IPO costs, and what the risks are.
About Rubicon Research
Rubicon Research is a drug development and manufacturing company. It helps create and produce medicines for other large pharma companies. The company is based in India but also works with foreign clients, especially in the United States. Rubicon is known for making complex and high-quality medicines that meet strict international standards.
The company has research centres in India and Canada. It focuses strongly on innovation and has many drug approvals from the United States Food and Drug Administration (USFDA). This helps it sell its products in foreign markets.
IPO Dates and Details
The Rubicon Research IPO will open on 9 October 2025 and close on 13 October 2025. The price band for each share is between ₹461 and ₹485.
The IPO includes two parts:
-
Fresh Issue: New shares worth ₹500 crore.
-
Offer for Sale: Existing shareholders will sell shares worth ₹877.50 crore.
So, the total issue size is about ₹1,377.50 crore.
The minimum number of shares one can buy is 30 shares per lot. That means retail investors need at least ₹14,000 to ₹15,000 if they apply at the upper price band.
Use of the Money
The money raised from the fresh issue will be used to pay some company debts, invest in growth, and support general business needs. Some of it will also go toward future expansions and new product development.
Company Strengths
Rubicon Research has several strong points:
-
It has many drug approvals from the USFDA.
-
The company works in regulated markets like the US, which builds trust.
-
It has a strong research and development (R&D) team.
-
Its products are known for high quality and innovation.
-
The company serves both Indian and international clients.
Because of these strengths, Rubicon Research has become a trusted name in the pharmaceutical industry.
Possible Risks
Every IPO has some risks, and Rubicon Research is no different. The main risks are:
Also Read: Atlanta Electricals IPO Review 2025: Should You Invest?
)
-
The company depends heavily on the US market. Changes in US laws or prices can affect profits.
-
Pharma companies face strict quality checks. If Rubicon fails any inspection, it could lose business.
-
Many of its new products are still in the research stage. If they fail to reach the market, it may affect future growth.
Why Investors Are Interested
Many investors are showing interest in Rubicon Research IPO because the company has strong R&D, a good track record, and a growing presence in global markets. The pharma industry also has steady demand, which can support the company’s long-term growth.
Conclusion
Rubicon Research IPO is an opportunity for investors who want to invest in a strong and growing pharmaceutical company. It has both strengths and risks. Investors should read the company’s financial reports and understand the risks before investing. With its focus on research, quality, and global expansion, Rubicon Research could be a good option for long-term investors.
Disclaimer: This article is for general information only. It does not provide financial advice. Please check the official company documents and talk to a financial advisor before investing in Rubicon Research IPO.
